Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2.

scientific article published on March 2002

Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID11836557

P2093author name stringGene Hung
Xiankui Li
Lan Kluwe
David Lim
Johng S Rhim
William Slattery
Rodolfo Faudoa
Zhu Xeu
P4510describes a project that usesHEI193Q54882275
P433issue3
P921main subjectcell lineQ21014462
P304page(s)475-482
P577publication date2002-03-01
P1433published inInternational Journal of OncologyQ6051527
P1476titleEstablishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2
P478volume20

Reverse relations

cites work (P2860)
Q30471189A novel imaging-compatible sciatic nerve schwannoma model
Q30388655Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Q33622690Comprehensive pharmacological profiling of neurofibromatosis cell lines
Q30406342Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Q36880469Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma.
Q39610985Enhanced in vivo imaging of metabolically biotinylated cell surface reporters
Q38770088Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells
Q39293667Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth
Q40126901Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter
Q35047921Inhibition of SIRT2 in merlin/NF2-mutant Schwann cells triggers necrosis
Q28728224Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells
Q39444934LIM domain kinases as potential therapeutic targets for neurofibromatosis type 2.
Q35836025Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism
Q28648056Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein.
Q36445494Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity
Q91713132Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas
Q30377885Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.
Q34062012Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas
Q34055933R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis
Q33795121Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models.
Q36634951Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1.
Q24301750Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer
Q30428483miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways
Q30401833p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Q54882275HEI193described by sourceP1343

Search more.